Literature DB >> 27607541

Deaths Related to Nontuberculous Mycobacterial Infections in the United States, 1999-2014.

Christopher Vinnard1, Sarah Longworth2, Alyssa Mezochow3, Amee Patrawalla4, Barry N Kreiswirth1, Keith Hamilton2.   

Abstract

RATIONALE: Unlike tuberculosis, nontuberculous mycobacterial disease is not reportable to public health authorities in the United States, and the total burden of disease is uncertain.
OBJECTIVES: To estimate the mortality of nontuberculous mycobacterial disease in the United States over a 15-year period and to identify temporal trends.
METHODS: The U.S. Multiple Cause of Death Files from 1999 through 2014 were searched for a listing of nontuberculous mycobacterial disease by International Classification of Diseases, Tenth Revision code as either the underlying or a contributing cause of death. Characteristics of individuals with nontuberculous mycobacteria-related deaths in the United States were summarized according to demographic characteristics. Age-adjusted mortality rates and rate ratios were calculated using bridged-race population estimates of U.S. census population data. Time trends were evaluated with negative binomial regression.
MEASUREMENTS AND MAIN RESULTS: There was a significant increase in nontuberculous mycobacteria-related deaths among individuals without a diagnosis of HIV infection (P = 0.004). Mortality rates increased with advancing age. Age-adjusted mortality rate ratios were lower for men (risk ratio [RR], 0.84; 95% confidence interval [CI], 0.80-0.87) compared with women, and were lower for Hispanic individuals (RR, 0.53; 95% CI, 0.49-0.56) and black, non-Hispanic persons (RR, 0.83; 95% CI, 0.77-0.88) compared with white, non-Hispanic individuals.
CONCLUSIONS: The mortality rate of nontuberculous mycobacterial disease among HIV-uninfected individuals has increased in the United States between 1999 and 2014. These deaths occurred disproportionately in older white women. Considering the concurrent decline in tuberculosis-related deaths, these findings demonstrate a shift in the epidemiology of fatal mycobacterial infections in the United States.

Entities:  

Keywords:  epidemiology; mortality; nontuberculous mycobacteria

Mesh:

Year:  2016        PMID: 27607541      PMCID: PMC5122483          DOI: 10.1513/AnnalsATS.201606-474BC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  15 in total

1.  Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems.

Authors:  D Rebecca Prevots; Pamela A Shaw; Daniel Strickland; Lisa A Jackson; Marsha A Raebel; Mary Ann Blosky; Ruben Montes de Oca; Yvonne R Shea; Amy E Seitz; Steven M Holland; Kenneth N Olivier
Journal:  Am J Respir Crit Care Med       Date:  2010-06-10       Impact factor: 21.405

Review 2.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

3.  Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries.

Authors:  Jennifer Adjemian; Kenneth N Olivier; Amy E Seitz; Steven M Holland; D Rebecca Prevots
Journal:  Am J Respir Crit Care Med       Date:  2012-02-03       Impact factor: 21.405

4.  Using multiple cause-of-death data to investigate associations and causality between conditions listed on the death certificate.

Authors:  Matthew D Redelings; Matthew Wise; Frank Sorvillo
Journal:  Am J Epidemiol       Date:  2007-04-09       Impact factor: 4.897

5.  Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection.

Authors:  Tomasz M Ziedalski; Peter N Kao; Noreen R Henig; Susan S Jacobs; Stephen J Ruoss
Journal:  Chest       Date:  2006-10       Impact factor: 9.410

6.  Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome.

Authors:  J M Reich; R E Johnson
Journal:  Chest       Date:  1992-06       Impact factor: 9.410

Review 7.  Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy.

Authors:  Petros C Karakousis; Richard D Moore; Richard E Chaisson
Journal:  Lancet Infect Dis       Date:  2004-09       Impact factor: 25.071

8.  The Burden of Pulmonary Nontuberculous Mycobacterial Disease in the United States.

Authors:  Sara E Strollo; Jennifer Adjemian; Michael K Adjemian; D Rebecca Prevots
Journal:  Ann Am Thorac Soc       Date:  2015-10

Review 9.  Underlying host risk factors for nontuberculous mycobacterial lung disease.

Authors:  Edward D Chan; Michael D Iseman
Journal:  Semin Respir Crit Care Med       Date:  2013-03-04       Impact factor: 3.119

10.  Maximum likelihood estimation of the negative binomial dispersion parameter for highly overdispersed data, with applications to infectious diseases.

Authors:  James O Lloyd-Smith
Journal:  PLoS One       Date:  2007-02-14       Impact factor: 3.240

View more
  21 in total

1.  Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population.

Authors:  Theodore K Marras; Christopher Vinnard; Quanwu Zhang; Keith Hamilton; Jennifer Adjemian; Gina Eagle; Raymond Zhang; Engels Chou; Kenneth N Olivier
Journal:  Respir Med       Date:  2018-10-22       Impact factor: 3.415

Review 2.  The Many Hosts of Mycobacteria 8 (MHM8): A conference report.

Authors:  Michelle H Larsen; Karen Lacourciere; Tina M Parker; Alison Kraigsley; Jacqueline M Achkar; Linda B Adams; Kathryn M Dupnik; Luanne Hall-Stoodley; Travis Hartman; Carly Kanipe; Sherry L Kurtz; Michele A Miller; Liliana C M Salvador; John S Spencer; Richard T Robinson
Journal:  Tuberculosis (Edinb)       Date:  2020-02-11       Impact factor: 3.131

Review 3.  Repositioning rifamycins for Mycobacterium abscessus lung disease.

Authors:  Uday S Ganapathy; Véronique Dartois; Thomas Dick
Journal:  Expert Opin Drug Discov       Date:  2019-06-14       Impact factor: 6.098

4.  High-Throughput Screening Identifies Synthetic Peptides with Antibacterial Activity against Mycobacterium abscessus and Serum Stability.

Authors:  Natalie Iannuzo; Yannik A Haller; Michelle McBride; Sabrina Mehari; John C Lainson; Chris W Diehnelt; Shelley E Haydel
Journal:  ACS Omega       Date:  2022-06-27

5.  Piperidine-4-Carboxamides Target DNA Gyrase in Mycobacterium abscessus.

Authors:  Dereje Abate Negatu; Andreas Beuchel; Abdeldjalil Madani; Nadine Alvarez; Chao Chen; Wassihun Wedajo Aragaw; Matthew D Zimmerman; Benoît Laleu; Martin Gengenbacher; Véronique Dartois; Peter Imming; Thomas Dick
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

Review 6.  Pulmonary non-tuberculous mycobacterial infections: current state and future management.

Authors:  Kai Ling Chin; Maria E Sarmiento; Nadine Alvarez-Cabrera; Mohd Nor Norazmi; Armando Acosta
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-18       Impact factor: 3.267

7.  Hospital-based antibiotic use in patients with Mycobacterium avium complex.

Authors:  Emily E Ricotta; Kenneth N Olivier; Yi Ling Lai; D Rebecca Prevots; Jennifer Adjemian
Journal:  ERJ Open Res       Date:  2018-11-02

Review 8.  Assessing Response to Therapy for Nontuberculous Mycobacterial Lung Disease: Quo Vadis?

Authors:  Christopher Vinnard; Alyssa Mezochow; Hannah Oakland; Ross Klingsberg; John Hansen-Flaschen; Keith Hamilton
Journal:  Front Microbiol       Date:  2018-11-20       Impact factor: 5.640

9.  Factors affecting in-hospital mortality of non-tuberculous mycobacterial pulmonary disease.

Authors:  Goh Tanaka; Taisuke Jo; Hiroyuki Tamiya; Yukiyo Sakamoto; Wakae Hasegawa; Hiroki Matsui; Kiyohide Fushimi; Hideo Yasunaga; Takahide Nagase
Journal:  BMC Infect Dis       Date:  2021-07-20       Impact factor: 3.090

10.  Optimization and Lead Selection of Benzothiazole Amide Analogs Toward a Novel Antimycobacterial Agent.

Authors:  Mary A De Groote; Thale C Jarvis; Christina Wong; James Graham; Teresa Hoang; Casey L Young; Wendy Ribble; Joshua Day; Wei Li; Mary Jackson; Mercedes Gonzalez-Juarrero; Xicheng Sun; Urs A Ochsner
Journal:  Front Microbiol       Date:  2018-09-20       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.